Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma
Objective: Sorafenib and lenvatinib have been recommended as standard tyro sine kinase inhibitors (TKIs) for progressive radioiodine-refractory differentiated thyroid carcinoma (RR-DTC).However, their efficacy remains limited with unresolved drug resistance.Therefore, we conceived this open-label study MENS FOOTWEAR based on real-world evidence to